学術雑誌論文 Intravenous immunoglobulin contributes to the control of antimelanoma differentiation-associated protein 5 antibody-associated dermatomyositis with palmar violaceous macules/papules

Koguchi-Yoshioka, H.  ,  Okiyama, N.  ,  Iwamoto, K.  ,  Matsumura, Y.  ,  Ogawa, T.  ,  Inoue, S.  ,  Watanabe, R.  ,  Fujimoto, M.

177 ( 5 )  , pp.1442 - 1446 , 2017-11 , wiley
ISSN:00070963
NII書誌ID(NCID):AA00574479
内容記述
Autoantibodies to melanoma differentiation-associated protein 5 (MDA5) are associated with a subset of patients with dermatomyositis (DM) who have rapidly progressive interstitial lung disease (RP-ILD) with poor prognosis. Intensive immunosuppressive therapy is initiated before irreversible lung damage can occur; however, there are few lines of evidence for the treatment of RP-ILD. Here, we report three cases of anti-MDA5 antibody-associated DM with RP-ILD in which the patients were treated with combined-modality therapy, including high-dose prednisolone, tacrolimus, intravenous cyclophosphamide and intravenous immunoglobulin (IVIG). In all three cases, serum ferritin levels, which are known to represent the disease activity of RP-ILD, were decreased after IVIG administration. IVIG might contribute to the control of the disease activity of anti-MDA5 antibody-positive DM. Moreover, palmar violaceous macules/papules around the interphalangeal joints, which was observed in all three cases in the incipient stage, might be a useful sign in suggesting a diagnosis of anti-MDA5 antibody-associated DM.
本文を読む

https://tsukuba.repo.nii.ac.jp/?action=repository_action_common_download&item_id=44645&item_no=1&attribute_id=17&file_no=1

このアイテムのアクセス数:  回

その他の情報